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Abstract 
Infection after total hip arthroplasties (THA) is a devastating complication with significant 
consequences for both the patients and the healthcare systems. In recent times, a two stage 
procedure using antibiotic-impregnated interim spacers has become the most popular 
treatment for late chronic hip joint infections after THA with success rates over 90%. In this 
review, we discuss the different types of spacers used in the treatment of chronically in-
fected THA and conclude that hip spacers are effective in the treatment of hip joint infec-
tions. 
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Introduction 
Periprosthetic infection after THA is a catastro-
phic complication which presents an enormous chal-
lenge to the orthopaedic community. Diagnosis is 
often difficult as no gold standard test is available; 
thus, the diagnosis relies on the surgeon’s judgement 
of the clinical presentation, the findings on physical 
examination and the interpretation of relevant inves-
tigations. The treatment goals are to attempt limb 
salvage and preserve joint function in an aging 
population with multiple co-morbidities and high risk 
of developing perioperative complications. Late 
chronic hip infections have been defined as those 
presenting more than 4 weeks from surgery, as op-
posed to acute infections occurring within 4 weeks of 
the operation [1]. 
Treatment of Chronic Hip Infections after 
THA  
Treatment options for chronic hip joint infections 
after THA have evolved from a single-stage direct 
exchange to two-stage and more recently multi-stage 
revision arthroplasty in several centres. The dilemma 
of identifying which patients are suitable for single 
versus multi stage revision remains unresolved. Long 
term suppressive antibiotics and salvage procedures 
such as girdlestone arthroplasty, arthrodesis and 
amputation have also been used in patients with high 
operative risk and in patients who are unwilling to 
have additional procedures. 
While single-stage revision has had good re-
sults[2-4], two-stage reimplantation remains the gold 
standard for the treatment of chronically infected 
THA today as the successful eradication of infection is 
well over 90% [5,6]. Furthermore, it permits unce-
mented reconstruction and the use of allografts at the 
second-stage which is particularly important given 
the frequency of femoral and acetabular defects asso-
ciated with THA infections [7-9]. 
The aim of a two-stage revision is to eradicate 
any residual bacteria after removal of the prosthesis 
and meticulous surgical debridement at the 




organism from tissue biopsies, determination of anti-
biotic sensitivity and appropriate adjustment of sys-
temic antibiotic therapy before reimplantation.  
The timing of the second stage is variable but is 
essentially based on clinical, radiological and labora-
tory evidence that infection has been overcome with 
an ESR and CRP levels returning to normal values. 
Antibiotic Loaded Cement   
The use of antibiotic loaded cement (ALC) in the 
form of spacers during the interval period to deliver 
antibiotics locally has become popular as it has in-
creased rates of infection control achieving up to 95% 
in several studies [10-12]. A number of papers have 
established the capability of ALC to deliver a much 
greater local concentration of antibiotic than is possi-
ble by systemic therapy [13-17] whilst preventing de-
bris from accumulating in the potential joint space and 
decreasing the risk of soft-tissue contractures [18]. 
Recent studies [19] suggest that the ALC may remove 
the need for systemic antibiotics in the interval period, 
thus decreasing costs and morbidity.  
Palacos bone cement has been widely used be-
cause of its superior elution characteristics and resis-
tance to fracture in comparison with other cement 
types [20,21]. However, Ensing et al [22] in a recent 
study showed that Copal bone cement has better re-
lease of gentamicin and may therefore be more effec-
tive in preventing biofilm formation than Palacos.  
When mixing the cement with antibiotics, it is 
important to leave as many large crystals intact as 
possible to create a more porous mixture to increase 
the antibiotic elution rate and apply the cement in the 
late stage of polymerisation to prevent interdigitation 
into bone to facilitate extraction at the 2nd stage revi-
sion [23]. Vacuum mixing whilst increasing the me-
chanical strength of cement by decreasing porosity, 
may also decrease antibiotic elution rates [15].  
Antibiotics added to bone cement are chosen 
according to the sensitivity of the infecting organism 
but conventionally have to fulfil the criteria estab-
lished by Murray [24] including: antibiotic safety, 
thermostability, hypoallergenicity, water solubility, 
adequate bactericidal spectrum and availability in a 
sterile powder form. The addition of antibiotics dis-
solved in liquid decreases the mechanical properties 
of the ALC which may increase the possibility of 
spacer fractures. Hsieh et al [25], however; followed 
up 42 patients undergoing two-stage revision arthro-
plasty for periprosthetic infection recently and con-
cluded that incorporation of liquid gentamicin in bone 
cement spacers led to effective drug delivery with 
systemic safety. The most commonly used antibiotics 
in ALC include tobramycin, gentamicin and vanco-
mycin [26]. The combination of vancomycin and one 
of the aminoglycosides provides a broad spectrum of 
coverage for organisms commonly encountered with 
deep periprosthetic infections whilst reducing the 
development of resistant strains [27]. Staphylococci in 
particular, rapidly develop resistance and therefore; 
single antibiotic treatment should never be used [28]. 
It is also important to keep in mind that if ALC had 
been used for the primary procedure, bacteria causing 
the infection may have already survived high con-
centrations of that antibiotic and will likely be resis-
tant if the same antibiotic is used in the spacer cement 
[29]. 
When used in temporary spacers, antibiotic 
dosages up to 20 g per 40 g of bone cement can be 
achieved without reported systemic side effects [30] 
whereas for fungal infections, 100 to 150 mg of am-
photericin B is typically added to the 40 g of bone 
cement in addition to other antibiotics chosen [31]. 
Mechanical strength of cement however; is influenced 
by the ratio in which the antibiotics are mixed into the 
cement and therefore, the total dose of antibiotics 
should not exceed 10% of the weight of the cement in 
order to avoid fracture of the cement spacer [27]. 
The implantation of an ALC spacer shortens the 
duration of systemic antibiotic therapy which lessens 
the likelihood of systemic toxicity and may result in a 
reduction in the emergence of drug resistant organ-
isms [32]. Likewise, complications associated with 
prolonged recumbency are also avoided due to early 
mobilisation [33]. Two-stage revision arthroplasty 
using ALC but without long-term systemic antibiotic 
therapy has also been reported by Stockley et al [19] 
in a recent study of 114 patients treated for chronic 
THA infections. Infection was successfully eradicated 
in 100 patients (87.7%) at a mean follow-up of two 
years. 
Spacers 
Spacers are classified as static or non-articulating 
spacers, medullary dowels, and articulating or mobile 
spacers. Despite the superior elution properties of 
ALC beads [34], they are rarely advocated nowadays 
due to the associated limb shortening causing higher 
energy requirements for gait, loss of tissue planes, 
contracted soft tissues and scarring which results in 
difficulty identifying and removing them at the 2nd 
stage procedure [17,35]. 
a) Static/nonarticulating spacers 
Static or simple block spacers allow local deliv-
ery of a high concentration of antibiotics and at the 
same time function to maintain joint space for future 




at the time of reimplantation and allow delivery of the 
antibiotics of choice according to sensitivities [23,36]. 
The disadvantage of a static spacer is that it does not 
allow physiological motion of the joint which results 
in periarticular scarring and muscle contractures 
adding to the morbidity and substantial impairment 
of patients’ normal daily activities during the pro-
longed course of treatment. Another drawback of the 
static spacer is bone loss attributed to migration of the 
block spacer. On the other hand, static spacers have 
b e e n  a s s o c i a t e d  w i t h  l e s s  g e n e r a t i o n  o f  d e b r i s  i n  
comparison with mobile spacers [23,36]. 
b) Medullary dowels 
A tapered cement dowel fashioned from the 
nozzle of a cement gun provides an excellent size and 
shape for a spacer to be inserted into the medullary 
canal during treatment of infected THA. A small bulb 
is left at the end of the dowel to prevent migration of 
the dowel down the femoral canal and help facilitate 
removal. After insertion, a moulded arthrodesis block 
or an articulating spacer may be inserted. Disadvan-
tages include the potential for proximal femoral mi-
gration and the fact that these cannot be used in pa-
tients with severe femoral bone loss [23,36]. 
c) Mobile/articulating spacers such as the prosthesis of 
antibiotic-loaded acrylic cement (PROSTALAC) 
The primary aim of this technique is to maintain 
function and soft tissue tension between stages to 
facilitate the second-stage reimplantation procedure. 
It has also been reported to reduce bone loss in com-
parison to static spacers [37]. Duncan and Beauchamp 
[38] first described the successful use of PROSTALAC 
for the 2-stage revision of infected THA. The cement 
of the femoral head articulated with the bone of the 
acetabular bed causing bone erosion and discomfort. 
An acetabular cement component was therefore in-
troduced; preventing loss of acetabular bone with a 
theoretical advantage of higher antibiotic elution due 
to the continuous friction of the cement components 
and the emergence of new antibiotic-eluting surfaces. 
However, the cement-on-cement articulation limited 
motion and  caused discomfort. The PROSTALAC 
system now consists of a  constrained cemented 
acetabular component and a femoral component with 
a modular head that is made intra-operatively with 
ALC surrounding a stainless steel endoskeleton, using 
a series of molds. A sufficient degree of antibiotic elu-
tion from PROSTALAC has been measured for a pe-
riod of over 4 months when at least 3.6 g of tobramy-
cin per 40 gram of bone cement and 1 gram of van-
comycin are used [18,39]. Whilst providing high doses 
of local antibiotic delivery, this system also allows 
earlier mobilisation out of bed and accelerated reha-
bilitation and discharge from the hospital between 
stages of treatment avoiding the complications asso-
ciated with prolonged hospital stay and immobilisa-
tion [40]. More recently, the option to use a preformed 
PROSTALAC equivalent with fixed low-dose antibi-
otic content has become available. Prefabricated 
molds of different sizes are also available, allowing 
the surgeon to select antibiotic dose and content. 
However, the disadvantages of preformed mobile 
spacers include limitation in implant sizes and anti-
biotic dose, often allowing delivery of only a single 
antibiotic to which the organisms being treated might 
not be susceptible [23,36]. Mobile spacers formed in 
the operating room have the advantage of adjustable 
antibiotic dosing. Disadvantages of such spacers in-
clude additional time to construct the implant in the 
operating room, the higher risk of fractures due to 
cement heterogeneity and inconsistencies in mixing 
and the potential risk of toxicity when high doses of 
antibiotics are added to the cement [23,36]. Various 
designs of articulating spacers have also been used 
including re-implantation of the excised prosthetic 
components after intraoperative sterilisation and spe-
cially designed reusable silicone or metal molds over 
metal endoskeletons such as rush pins and Kirschner 
wires with overall good results [41, 42]. 
After radical debridement, removal of all com-
ponents and taking at least five tissue samples for 
bacteriologic and histologic assessments, the 
acetabular component is cemented loosely and femo-
ral fixation is achieved by means of a press-fit or late 
proximal cementation so that both are removed easily 
at the second stage without damaging bone stock. 
Postoperatively, the patient is allowed to mobilise 
partial weight-bearing with crutches and is dis-
charged home when deemed safe. Antibiotic therapy 
tailored to the sensitivities of intraoperative cultures is 
continued for 4 to 6 weeks. The decision to proceed 
with insertion of a new prosthesis is determined if the 
culture of a hip aspirate performed 4 weeks after dis-
continuation of antibiotics is negative and inflamma-
tory markers suggest resolution of infection (ESR < 
30mm/hr and CRP < 10mg/L). At the second stage, 
the spacer is removed without difficulty and the un-
derlying cement mantle is fragmented and removed 
piecemeal, without sacrificing bone stock. Appropri-
ate implants are then reimplanted with either ce-
mented or cementless components, and allografts 
may be used in cases of severe bone loss [38]. After the 
reimplantation procedure, patients are followed 
clinically and with ESR and CRP levels for any signs 
of recurring infection. Systemic antibiotics are discon-




evidence of ongoing infection, a repeat debridement 
procedure is performed with new culture specimens 
sent for microbiology and systemic antibiotics are 
adjusted accordingly. At this stage, either a repeat 
PROSTALAC insertion or a salvage procedure is con-
sidered after discussion of treatment options with the 
patient. 
Conclusions 
In conclusion, treatment of late chronic hip joint 
infections after THA is a challenging problem. The 
gold standard remains a two-stage revision arthro-
plasty using antibiotic-impregnated cement spacers 
which achieves an infection control rate over 90%. 
Articulating spacers provide the advantages of main-
taining limb length and joint mobility, minimising 
soft-tissue contracture and scarring, and facilitating 
second-stage reimplantation and therefore, should be 
used as the first option of treatment for late chronic 
hip joint infections. 
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